A couple of people objected to my use of the word “failing” in my previous article. I’ve therefore updated it to suggest that they share price is more… gracefully declining.
Yep, I guess we'll see how that pans out. Actually seems healthier to have this being a smaller fraction of overall revenue. Too much focus on a small number of very large customers doesn't seem great.
Emirati Genome Project is apparently stretching its timelines - less near-term ONT revenue
https://otp.tools.investis.com/clients/uk/oxford_nanopore/rns/regulatory-story.aspx?cid=2700&newsid=1746845
Yep, I guess we'll see how that pans out. Actually seems healthier to have this being a smaller fraction of overall revenue. Too much focus on a small number of very large customers doesn't seem great.